A novel 18F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy

(2022) Kyle M. Garland et al.   CHEMICAL REVIEWS

cGAS-STING pathway expression as a prognostic tool in NSCLC

(2021) Kristine Raaby Gammelgaard et al.   Translational Lung Cancer Research

First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET

(2021) Xin Zhou et al.   JOURNAL OF NUCLEAR MEDICINE

cGAS-STING, an important pathway in cancer immunotherapy

(2020) Minlin Jiang et al.   Journal of Hematology & Oncology

Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer

(2019) Yan Xing et al.   JOURNAL OF NUCLEAR MEDICINE

Degree of STING activation is associated with disease outcomes

(2019) Qiongyuan Hu et al.   GUT

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

(2019) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

STING pathway agonism as a cancer therapeutic

(2019) Blake A. Flood et al.   IMMUNOLOGICAL REVIEWS

DNA sensing by the cGAS–STING pathway in health and disease

(2019) Mona Motwani et al.   NATURE REVIEWS GENETICS

The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer

(2019) John Kwon et al.   Cancer Discovery

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Design of amidobenzimidazole STING receptor agonists with systemic activity

(2018) Joshi M. Ramanjulu et al.   NATURE

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

(2018) Frederike Bensch et al.   NATURE MEDICINE

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2018) Kelsey E. Sivick et al.   Cell Reports

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

(2016) Henrique Lemos et al.   CANCER RESEARCH

Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer

(2016) Qing Chen et al.   NATURE

Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal

(2015) Ding Liang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase

(2013) Pu Gao et al.   CELL

STING is a direct innate immune sensor of cyclic di-GMP

(2011) Dara L. Burdette et al.   NATURE

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

(2008) Hiroki Ishikawa et al.   NATURE